Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection.


Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 29 05 2021
revised: 02 07 2021
accepted: 20 07 2021
pubmed: 3 8 2021
medline: 23 9 2021
entrez: 2 8 2021
Statut: ppublish

Résumé

The antibody response to SARS-CoV-2 has not yet fully defined, but the availability of sensitive and specific serological assays is crucial to observe the presence of specific antibodies against the human receptor binding domain (S-RBD) and high specificity ACE-2-binding antibodies or neutralizing antibodies (NT) in response to vaccines. Indeed, these peculiar antibodies should prevent viral interaction between RBD and Angiotensin-Converting Enzyme 2 (ACE2) receptor, located on surface of host cells. In this study, 72 samples from 37 hospitalized COVID-19 patients and 35 not-hospitalized patients were analyzed longitudinally. The detection of S-RBD and NT antibodies was carried out using CLIA tests. Hospitalized patients showed elevated serum levels of S-RBD (97.22%) and NT (77.78%) antibodies, differently, not-hospitalized, who were paucisymptomatic or asymptomatic patients, showed lower serum levels of S-RBD (65.71%) and NT (38.14%) antibodies. The results suggest that the NT serum level is strongly related to disease severity (p < 0.001) and to the serum level of S-RBD antibodies (p < 0.0001).

Identifiants

pubmed: 34339963
pii: S1567-5769(21)00649-4
doi: 10.1016/j.intimp.2021.108013
pmc: PMC8313542
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108013

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
Clin Chim Acta. 2020 Dec;511:28-32
pubmed: 33002475
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
J Med Virol. 2021 Apr;93(4):2160-2167
pubmed: 33064340
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
EBioMedicine. 2020 Dec;62:103101
pubmed: 33160207

Auteurs

Flaminia Tomassetti (F)

Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy; Lifebrain srl, Viale Roma 190/A, Guidonia Montecelio, Rome, Italy.

Marzia Nuccetelli (M)

Department of Laboratory Medicine, Tor Vergata University Hospital, Rome, Italy.

Serena Sarubbi (S)

Department of Experimental Medicine, University of Tor Vergata, Rome, Italy.

Francesca Gisone (F)

Department of Experimental Medicine, University of Tor Vergata, Rome, Italy.

Marco Ciotti (M)

Department of Laboratory Medicine, Virology Unit, Tor Vergata University Hospital, Rome, Italy.

Francesco Spinazzola (F)

Lifebrain srl, Viale Roma 190/A, Guidonia Montecelio, Rome, Italy.

Cristina Ricotta (C)

Lifebrain Liguria, Via G.B. Monti, 109 R, Genoa, Italy.

Monica Cagnoli (M)

Lifebrain Liguria, Via G.B. Monti, 109 R, Genoa, Italy.

Monica Borgatti (M)

Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.

Marco Iannetta (M)

Department of Functional Area of Integrated Care Services, Infectious Diseases Clinic, Tor Vergata University Hospital, Rome, Italy; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Massimo Andreoni (M)

Department of Functional Area of Integrated Care Services, Infectious Diseases Clinic, Tor Vergata University Hospital, Rome, Italy; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Graziella Calugi (G)

Lifebrain srl, Viale Roma 190/A, Guidonia Montecelio, Rome, Italy.

Massimo Pieri (M)

Lifebrain srl, Viale Roma 190/A, Guidonia Montecelio, Rome, Italy; Department of Laboratory Medicine, Tor Vergata University Hospital, Rome, Italy; Department of Experimental Medicine, University of Tor Vergata, Rome, Italy. Electronic address: massimo.pieri@uniroma2.it.

Sergio Bernardini (S)

Department of Laboratory Medicine, Tor Vergata University Hospital, Rome, Italy; Department of Experimental Medicine, University of Tor Vergata, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH